Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Taobi Huang(First Hospital of Lanzhou University), Yuping Wang(King Center), Longquan Li(First Hospital of Lanzhou University), Hui Wei(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuan Liang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xia Chen(Jinan University), Huiyun Zhang(First Hospital of Lanzhou University), Weiming Sun(First Hospital of Lanzhou University)
Cited by 45
Related Papers
COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis
|Journal of Medical Virology|2020|1.6k
Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells
|Cell Reports|2022|465
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease
|Journal of Medicinal Chemistry|2016|165
Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma
|Cancer Discovery|2022|137